No profile data available.
ImmuCell Corporation (ICCC) is a healthcare company in the animal healthcare items industry, based in Portland, United States, with about 73 full-time employees.
It reported revenue of $27.64 million for fiscal year 2025, up 4.3% from fiscal year 2024, and net income of -$1.04 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $7.19 million, up 11.5% from a year before. Its largest business segment, Scours, brought in 99% of segment revenue in fiscal year 2025; United States was the largest region with 88%. Its market capitalization was $89.01 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis.
ImmuCell reported $27.64 million in revenue for fiscal year 2025, up 4.3% from $26.49 million in fiscal year 2024. In Q2 2026 revenue was $7.19 million.
Scours, with $27.45 million or 99% of segment revenue in fiscal year 2025. Next: Mastitis (1%).
United States: 88% of revenue by region in fiscal year 2025, followed by Other (12%).
$89.01 million as of October 9, 2026.
Listed companies of a similar size in the same industry (animal healthcare items) include Zoetis Inc. (ZTS), Elanco Animal Health Incorporated (ELAN), Phibro Animal Health Corporation (PAHC), Zhengye Biotechnology Holding Limited (ZYBT).